Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC

We established the lipidomics-based predictive model for the efficacy of non-oncogene addicted advanced NSCLC patients treated with first-line chemotherapy plus ICI and elucidated a novel mechanism whereby LA potentiates immunotherapy by regulating the PD-L1 pathway. These findings provide dual theoretical foundations for personalized treatment strategies and the development of immunoadjuvants.